Journal ArticleDOI
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Alan Menter,Bruce Strober,Daniel H. Kaplan,Dario Kivelevitch,Elizabeth Farley Prater,Benjamin K. Stoff,April W. Armstrong,Cody Connor,Kelly M. Cordoro,Dawn Marie R. Davis,Boni E. Elewski,Joel M. Gelfand,Kenneth B. Gordon,Alice B. Gottlieb,Arthur Kavanaugh,Matthew Kiselica,Neil J. Korman,Daniela Kroshinsky,Mark Lebwohl,Craig L. Leonardi,Jason Lichten,Henry W. Lim,Nehal N. Mehta,Amy S. Paller,Sylvia L. Parra,Arun L. Pathy,Reena N. Rupani,Michael Siegel,Emily B. Wong,Jashin J. Wu,Vidhya Hariharan,Craig A. Elmets +31 more
TLDR
The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks.Abstract:
Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks.read more
Citations
More filters
Journal ArticleDOI
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review
TL;DR: Therapeutic advancements for moderate to severe plaque psoriasis include biologics that inhibit TNF-α, p40IL-12/23, IL-17, and p19IL-23, as well as an oral phosphodiesterase 4 inhibitor.
Journal ArticleDOI
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Peter Nash,Andreas Kerschbaumer,Thomas Dörner,Maxime Dougados,Roy Fleischmann,Klaus Geissler,Iain B. McInnes,Janet E. Pope,Désirée van der Heijde,Michaela Stoffer-Marx,Tsutomu Takeuchi,Michael Trauner,Kevin L. Winthrop,Maarten de Wit,Daniel Aletaha,Xenofon Baraliakos,Wolf-Henning Boehncke,Paul Emery,John D. Isaacs,Joel M. Kremer,Eun Bong Lee,Walter P. Maksymowych,Marieke Voshaar,Lai-Shan Tam,Yoshiya Tanaka,Filip Van den Bosch,Rene Westhovens,Ricardo Machado Xavier,Josef S Smolen +28 more
TL;DR: The consensus provides an assessment of evidence for efficacy and safety of an important therapeutic class with guidance on issues of practical management of Janus kinase inhibitors.
Journal ArticleDOI
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Alan Menter,Kelly M. Cordoro,Dawn Marie R. Davis,Daniela Kroshinsky,Amy S. Paller,April W. Armstrong,Cody Connor,Boni E. Elewski,Joel M. Gelfand,Kenneth B. Gordon,Alice B. Gottlieb,Daniel H. Kaplan,Arthur Kavanaugh,Matthew Kiselica,Dario Kivelevitch,Neil J. Korman,Mark Lebwohl,Craig L. Leonardi,Jason Lichten,Henry W. Lim,Nehal N. Mehta,Sylvia L. Parra,Arun L. Pathy,Elizabeth Farley Prater,Reena N. Rupani,Michael Siegel,Benjamin K. Stoff,Bruce Strober,Emily B. Wong,Jashin J. Wu,Vidhya Hariharan,Craig A. Elmets +31 more
TL;DR: This guideline addresses important clinical questions that arise in psoriasis management and provides evidence-based recommendations, recognizing the unique physiology, pharmacokinetics, and patient-parent-provider interactions of patients younger than 18 years old.
Journal ArticleDOI
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Andrew Blauvelt,Craig L. Leonardi,Melinda Gooderham,Kim A. Papp,Sandra Philipp,Jashin J. Wu,Atsuyuki Igarashi,Mary Flack,Ziqian Geng,Tianshuang Wu,Anne Camez,David A. Williams,Richard G. Langley +12 more
TL;DR: Findings support the use of 12-week risankizumab dosing as an efficacious and well-tolerated regimen for maintenance of clinical efficacy in patients with moderate to severe plaque psoriasis.
Journal Article
Current Developments in the Immunology of Psoriasis.
Franziska Grän,Andreas Kerstan,Edgar Serfling,Matthias Goebeler,Khalid Muhammad,Khalid Muhammad +5 more
TL;DR: Different roles of T cells, B cells, and cytokines for the immunopathology and disease course of psoriasis are described.
References
More filters
Journal ArticleDOI
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Filip Baert,Maja Noman,Severine Vermeire,Gert Van Assche,Geert D' Haens,An Carbonez,Paul Rutgeerts +6 more
TL;DR: The development of antibodies against infliximab is associated with an increased risk of infusion reactions and a reduced duration of response to treatment, and concomitant immunosuppressive therapy reduces the magnitude of the immunogenic response.
Journal ArticleDOI
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi,Alexa B. Kimball,Kim A. Papp,Newman Yeilding,Cynthia Guzzo,Y. Wang,Shu Li,Lisa T. Dooley,Kenneth B. Gordon +8 more
TL;DR: Ustekinumab seems to be efficacious for the treatment of moderate-to-severe psoriasis; dosing every 12 weeks maintains efficacy for at least a year in most patients.
Journal ArticleDOI
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G. Langley,Boni E. Elewski,Mark Lebwohl,Kristian Reich,Christopher E.M. Griffiths,Kim A. Papp,Lluís Puig,Hidemi Nakagawa,Lynda Spelman,Bárður Sigurgeirsson,Enrique Rivas,Tsen-Fang Tsai,Norman Wasel,Stephen K. Tyring,Thomas Salko,Isabelle Hampele,Marianne Notter,Alexander Karpov,Silvia Helou,Charis Papavassilis +19 more
TL;DR: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target and the rates of infection were higher with secuk inumab than with placebo in both studies and were similar to those with etanercept.
Journal ArticleDOI
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
TL;DR: Etanercept offers patients with psoriatic arthritis and psoriasis a new therapeutic option for control of their disease.
Journal ArticleDOI
Etanercept as monotherapy in patients with psoriasis
Craig L. Leonardi,Jerold Powers,Robert Matheson,Bernard S. Goffe,Ralph Zitnik,Andrea Wang,Alice B. Gottlieb +6 more
TL;DR: The treatment of psoriasis with etanercept led to a significant reduction in the severity of disease over a period of 24 weeks, paralleled by improvements in global assessments by physicians and the patients and in quality-of-life measures.
Related Papers (5)
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G. Langley,Boni E. Elewski,Mark Lebwohl,Kristian Reich,Christopher E.M. Griffiths,Kim A. Papp,Lluís Puig,Hidemi Nakagawa,Lynda Spelman,Bárður Sigurgeirsson,Enrique Rivas,Tsen-Fang Tsai,Norman Wasel,Stephen K. Tyring,Thomas Salko,Isabelle Hampele,Marianne Notter,Alexander Karpov,Silvia Helou,Charis Papavassilis +19 more
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl,Bruce Strober,Alan Menter,Kenneth B. Gordon,Jolanta Weglowska,Lluís Puig,Kim A. Papp,Lynda Spelman,Darryl Toth,Francisco A. Kerdel,April W. Armstrong,Georg Stingl,Alexa B. Kimball,Hervé Bachelez,Jashin J. Wu,Jeffrey J. Crowley,Richard G. Langley,Tomasz Blicharski,Carle Paul,Jean-Philippe Lacour,Stephen K. Tyring,Leon H Kircik,Sergio Chimenti,Kristina Callis Duffin,Jerry Bagel,John Koo,Gary Aras,Joanne Li,Wenjie Song,Cassandra E Milmont,Yifei Shi,Ngozi Erondu,Paul Klekotka,Brian L Kotzin,Ajay Nirula +34 more